Characteristics and Outcomes of Adolescents (15–18 Years) with Chronic Myelogenous Leukemia (CML) in Chronic Phase: The Experience of the International Registry of Childhood CML †

Millot F, Froment M, Durocher L, Metzler M, De Moerloose B, Brandalise SR, Borisevich M, Sedlacek P, Meral Gunes A, Lausen B, Molines Honrubia A, Jakovljevic G, Versluys B, Kalwak K, Hraskova A, Suttorp M (2026)

Publication Type: Journal article

Publication year: 2026

Journal

Cancers MDPI

Book Volume: 18

Article Number: 1959

Journal Issue: 12

DOI: 10.3390/cancers18121959

Abstract

Background: Chronic myeloid leukemia (CML) is a rare disease in children and adolescents. Discrepancies have been reported regarding the outcomes of adolescents, most of whom have been studied with younger or older patients not separately. Methods: The International Registry of Pediatric CML (I-CML-Ped Study) retrospectively and prospectively enrolled 614 patients less than 18 years old. Data from adolescents (15–18 years) with CML in chronic phase (CML-CP) were analyzed and compared to data from children less than 15 years old enrolled during the same period. Results: In total, 132 out of 144 adolescents presented with CML-CP: palpable spleen was reported in 67%, and the median leukocyte count was 181 G/L [interquartile range, 70–327]. Responses to treatment and outcome were analyzed in 124 adolescents with imatinib as first-line treatment: the cumulative incidence of major molecular responses (MMR) at months 12 and 36 was 33.4% (95% confidence interval CI, 24.9–41.9) and 79.8% (95% CI, 71.8–87.7), respectively. With a median follow-up of 4 years (95% CI: 3.5–4.9), 49 (40%) of these 124 patients were switched to another treatment, 11 (9%) patients progressed to the advanced phase, and the five-year overall survival rate was 95.2% (95% CI, 90.8–99.9%). We did not find significant statistical differences between these adolescents and younger children receiving imatinib in terms of response (complete cytogenetic response, MMR) and outcome (progression-free survival, overall survival). Conclusions: Response to treatment and outcomes in adolescents with CML-CP in the tyrosine kinase inhibitor era are satisfying without statistically significant difference from results observed in younger children.

Authors with CRIS profile

Markus Metzler Professur für Kinder- und Jugendmedizin mit dem Schwerpunkt Pädiatrische Onkologie und Hämatologie

Involved external institutions

Belarusian Research Center for Pediatric Oncology, Hematology and Immunology BY Belarus (BY) Motol University Hospital / Fakultní nemocnice v Motole CZ Czech Republic (CZ) Centre hospitalier universitaire de Poitiers (CHU de Poitiers) FR France (FR) University Hospital Ghent BE Belgium (BE) Hospital Boldrini / Centro Infantil Boldrini BR Brazil (BR) Rigshospitalet DK Denmark (DK) Children's Hospital Zagreb / Klinika za dječje bolesti Zagreb HR Croatia (HR) Wilhelmina Kinderziekenhuis NL Netherlands (NL) Wrocław Medical University / Uniwersytet Medyczny we Wrocławiu PL Poland (PL) National Institute of Children’s Diseases (NÚDCH) SK Slovakia (SK) Universitätsklinikum Carl Gustav Carus Dresden DE Germany (DE)

How to cite

APA:

Millot, F., Froment, M., Durocher, L., Metzler, M., De Moerloose, B., Brandalise, S.R.,... Suttorp, M. (2026). Characteristics and Outcomes of Adolescents (15–18 Years) with Chronic Myelogenous Leukemia (CML) in Chronic Phase: The Experience of the International Registry of Childhood CML †. Cancers, 18(12). https://doi.org/10.3390/cancers18121959

MLA:

Millot, Frédéric, et al. "Characteristics and Outcomes of Adolescents (15–18 Years) with Chronic Myelogenous Leukemia (CML) in Chronic Phase: The Experience of the International Registry of Childhood CML †." Cancers 18.12 (2026).

BibTeX: Download